This open-label, single centre pilot study was designed to evaluate safety and tolerability of the combination of the drugs isosorbide dinitrate, a nitric oxide donor, and ibuprofen, a non steroid anti-inflammatory drug, in a cohort of adult dystrophic patients (Duchenne, Becker and Limb-Girdle Muscular Dystrophy). Seventy-one patients were recruited: 35, treated with the drug combination for 12 months, and 36 untreated. Safety and adverse events were assessed by reported signs and symptoms, physical examinations, blood tests, cardiac and respiratory function tests. Exploratory outcomes measure, such as the motor function measure scale, were also applied. Good safety and tolerability profiles of the long-term co-administration of the drugs were demonstrated. Few and transient side effects (i.e. headache and low blood pressure) were reported. Additionally, exploratory outcomes measures were feasible in all the disease population studied and evidenced a trend towards amelioration that reached statistical significance in one dimension of the MFM scale. Systemic administration of ibuprofen and isosorbide dinitrate provides an adequate safety margin for clinical studies aimed at assessing efficacy. (c) 2012 Elsevier Ltd. All rights reserved.

Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies : evidence from a safety study with pilot efficacy measures in adult dystrophic patients / M.G. D'Angelo, S. Gandossini, F.M. Boneschi, C. Sciorati, S. Bonato, E. Brighina, G.P. Comi, A.C. Turconi, F. Magri, G. Stefanoni, S. Brunelli, N. Bresolin, D. Cattaneo, E. Clementi. - In: PHARMACOLOGICAL RESEARCH. - ISSN 1043-6618. - 65:4(2012 Apr), pp. 472-479.

Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies : evidence from a safety study with pilot efficacy measures in adult dystrophic patients

M.G. D'Angelo;S. Gandossini;S. Bonato;E. Brighina;G.P. Comi;F. Magri;N. Bresolin;D. Cattaneo;E. Clementi
2012

Abstract

This open-label, single centre pilot study was designed to evaluate safety and tolerability of the combination of the drugs isosorbide dinitrate, a nitric oxide donor, and ibuprofen, a non steroid anti-inflammatory drug, in a cohort of adult dystrophic patients (Duchenne, Becker and Limb-Girdle Muscular Dystrophy). Seventy-one patients were recruited: 35, treated with the drug combination for 12 months, and 36 untreated. Safety and adverse events were assessed by reported signs and symptoms, physical examinations, blood tests, cardiac and respiratory function tests. Exploratory outcomes measure, such as the motor function measure scale, were also applied. Good safety and tolerability profiles of the long-term co-administration of the drugs were demonstrated. Few and transient side effects (i.e. headache and low blood pressure) were reported. Additionally, exploratory outcomes measures were feasible in all the disease population studied and evidenced a trend towards amelioration that reached statistical significance in one dimension of the MFM scale. Systemic administration of ibuprofen and isosorbide dinitrate provides an adequate safety margin for clinical studies aimed at assessing efficacy. (c) 2012 Elsevier Ltd. All rights reserved.
Anti-inflammatory drug; Muscular dystrophies; Nitric oxide donor; Pharmacological treatment; Safety; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Female; Humans; Ibuprofen; Isosorbide Dinitrate; Male; Middle Aged; Muscular Dystrophies; Nitric Oxide Donors; Treatment Outcome; Young Adult; Pharmacology
Settore MED/26 - Neurologia
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1043661812000072-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 422.04 kB
Formato Adobe PDF
422.04 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/256576
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 39
  • ???jsp.display-item.citation.isi??? 36
social impact